Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Corticobasal degeneration.

N P Stover1, R L Watts

  • 1Movement Disorder Program, Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA.

Seminars in Neurology
|May 11, 2001
PubMed
Summary

Corticobasal degeneration (CBD) is a challenging neurodegenerative disease often underdiagnosed due to its varied symptoms. Early recognition of motor and cognitive dysfunction is crucial for better patient management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Connectomic Basis for Tremor Control in Stereotactic Radiosurgical Thalamotomy.

AJNR. American journal of neuroradiology·2023
Same author

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.

Neurology·2007
Same author

Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study.

Neurology·2006
Same author

Occupation and parkinsonism in three movement disorders clinics.

Neurology·2005
Same author

Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome.

Sleep medicine·2005
Same author

Ophthalmologic features of Parkinson's disease.

Neurology·2004

Area of Science:

  • Neurology
  • Neuroscience
  • Pathology

Background:

  • Corticobasal degeneration (CBD) is an underrecognized neurodegenerative disorder.
  • It presents with a heterogeneous mix of motor and cognitive impairments, often overlapping with other conditions.
  • Diagnosis is challenging due to symptom variability and overlapping pathology with other neurodegenerative diseases.

Purpose of the Study:

  • To highlight the diagnostic challenges of Corticobasal degeneration (CBD).
  • To review the characteristic clinical and pathological features of CBD.
  • To emphasize the need for further research into molecular abnormalities and biomarkers for improved diagnosis and treatment.

Main Methods:

  • Review of clinical features, including motor symptoms (akinesia, rigidity, apraxia, dystonia, alien limb) and cognitive decline.
  • Description of pathological findings: asymmetric frontoparietal neuronal loss, gliosis, achromatic neurons, nigral degeneration, and subcortical involvement.
  • Discussion of the utility and limitations of neuroimaging and electrophysiologic studies in CBD diagnosis.

Main Results:

  • Characteristic initial motor symptoms include akinesia, rigidity, and apraxia.
  • Cognitive decline, leading to dementia diagnosis, is a common and often misdiagnosed presentation.
  • Dopaminergic therapy is frequently ineffective, and treatment remains largely symptomatic and minimally effective.

Conclusions:

  • CBD should be considered in patients with combined motor and cognitive dysfunction and cortical/subcortical features.
  • Current diagnostic tools (neuroimaging, electrophysiology) offer supportive but not specific evidence.
  • Further research is essential to identify molecular abnormalities and biomarkers for improved diagnosis and therapeutic strategies for Corticobasal degeneration.

Related Experiment Videos